Spotlight on Pediatrics

Credits: 0.75 CME
Improving Severe Asthma Control through Comprehensive Patient Assessment and Tailored Treatment Selection
William Busse, MD
Integrity Continuing Education, Inc.

Improving Severe Asthma Control through Comprehensive Patient Assessment and Tailored Treatment Selection

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit
Released: November 20, 2018
Expires: November 20, 2019
1 hour to complete

Provided by


Integrity Continuing Education, Inc.

Target Audience

This educational initiative has been designed for allergists, pulmonologists, and otolaryngic allergists involved in the management of patients with severe asthma.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Describe clinical criteria for severe asthma and outline an approach to assessing symptom control and disease burden
  • Identify known phenotypes of severe asthma
  • Develop an approach to the treatment of severe asthma that is personalized to the individual patient and describe the most recent clinical data on new and emerging therapies for severe asthma
  • Identify strategies for improving communication to promote collaborative decision-making and the ability to self-manage among patients with severe asthma

Activity Description

Despite recent advances in our understanding of the pathophysiology of asthma and a corresponding expansion of targeted treatment modalities, severe asthma care continues to be a challenge in clinical practice. This program is designed to address this issue by imparting clinical knowledge and competence to clinicians that will promote comprehensive assessment and highly personalized treatment of patients whose symptoms meet the criteria for severe asthma. In addition, this initiative is also targeted at providing clinicians with guidance on strategies for improving disease awareness, increasing collaborative decision-making, and promoting self-management among patients with severe asthma.

Faculty

William W. Busse, MD
Professor of Medicine
Division of Allergy, Pulmonary, and Critical Care Medicine
School of Medicine and Public Health
University of Wisconsin
Madison, Wisconsin


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

William W. Busse, MD
Royalty: Elsevier
Consulting Fees: AstraZeneca Pharmaceuticals LP, Genentech, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Sanofi Genzyme and Regeneron Pharmaceuticals, Teva Pharmaceuticals
Data Monitoring Boards/Study Oversight Committees: Boston Scientific, Genentech, ICON Clinical Research Ltd.

The Integrity CE planners and managers have nothing to disclose.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of November 20, 2018 through November 20, 2019 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Sanofi Genzyme and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information for Questions About the Activity

For information about the ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or via email at information@integrityce.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Statement of Commercial Support

Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Pediatrics Presentations

0.75 CME
Vindico
Advances in the Treatment of Peanut Allergy: Rapid Response from Seattle

Advances in the Treatment of Peanut Allergy: Rapid Response from Seattle

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credits
Released: November 30, 2018
Expires: November 30, 2019
0.75 hours to complete

Accredited By

This continuing medical education activity is provided by Vindico Medical Education.

Faculty

Activity Chair:
J. Andrew Bird, MD
J. Andrew Bird, MD
Associate Professor of Pediatrics
Division of Allergy and Immunology
University of Texas Southwestern Medical Center
Director, Food Allergy Center
Children’s Medical Center of Dallas
Dallas, TX

Disclosure: Consulting Fee: Aimmune, DBV Technologies, Pharm-Olam
Non-CME Services Fees: Aimmune, DBV Technologies
Contracted Research: Aimmune, DBV Technologies


Faculty:
Ruchi S. Gupta, MD, MPH
Ruchi S. Gupta, MD, MPH
Professor of Pediatrics and Medicine
Northwestern Feinberg School of Medicine
Director
Science and Outcomes of Allergy and Asthma Research Team
Clinical Attending
Ann and Robert H. Lurie Children's Hospital Chicago
Chicago, IL

Disclosure: Consulting Fee: Aimmune, BEFORE Brands, DBV Technologies, Kaleo Pharma
Contracted Research: Thermo Fisher Scientific, United Health Group


Edwin H. Kim, MD, MS
Edwin H. Kim, MD, MS
Director, UNC Food Allergy Initiative
University of North Carolina at Chapel Hill
Chapel Hill, NC

Disclosure: Consulting Fee: Aimmune, DBV Technologies
Contracted Research: Aimmune, Astellas, DBV Technologies, FARE, HAL Allergy
Research Support: Wallace Foundation


Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.


Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.


Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Activity Description

The prevalence of peanut allergy in adults and children continues to increase, significantly disrupting the lives of the millions of affected individuals as well as their families. Although no therapies have been approved for the treatment of peanut allergies, several are currently being evaluated in clinical studies, providing the potential for safe and effective therapeutic options. Within this Rapid Response from Seattle, experts in the field examine the prevalence and burden of IgE-mediated food allergy with a focus on peanut allergy, assess the latest clinical data regarding the use of oral immunotherapy for the treatment of patients with peanut allergy, and evaluate the challenges associated with heterogeneity in terminology used in immunotherapy clinical trials for the management of patients with peanut allergy.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Examine the prevalence and burden of IgE-mediated food allergy, with a focus on peanut allergy.
  • Assess the latest clinical data regarding the use of oral immunotherapy for the treatment of patients with peanut allergy.
  • Examine the challenges associated with heterogeneity in terminology used in immunotherapy clinical trials for the management of patients with peanut allergy.

Target Audience

The intended audience for the activity is allergists, immunologists and other health care professionals involved in the treatment of patients with food allergies, particularly peanut allergy.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s) Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Aimmune Therapeutics.

Disclaimer Statement/Disclosure of Unlabeled Use

The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Contact Information for Questions About the Activity

Contact us at CME@VindicoCME.com

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2018 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

0.75 CME
Integrity Continuing Education, Inc.
Improving Severe Asthma Control through Comprehensive Patient Assessment and Tailored Treatment Selection

Improving Severe Asthma Control through Comprehensive Patient Assessment and Tailored Treatment Selection

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit
Released: November 20, 2018
Expires: November 20, 2019
1 hour to complete

Provided by


Integrity Continuing Education, Inc.

Target Audience

This educational initiative has been designed for allergists, pulmonologists, and otolaryngic allergists involved in the management of patients with severe asthma.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Describe clinical criteria for severe asthma and outline an approach to assessing symptom control and disease burden
  • Identify known phenotypes of severe asthma
  • Develop an approach to the treatment of severe asthma that is personalized to the individual patient and describe the most recent clinical data on new and emerging therapies for severe asthma
  • Identify strategies for improving communication to promote collaborative decision-making and the ability to self-manage among patients with severe asthma

Activity Description

Despite recent advances in our understanding of the pathophysiology of asthma and a corresponding expansion of targeted treatment modalities, severe asthma care continues to be a challenge in clinical practice. This program is designed to address this issue by imparting clinical knowledge and competence to clinicians that will promote comprehensive assessment and highly personalized treatment of patients whose symptoms meet the criteria for severe asthma. In addition, this initiative is also targeted at providing clinicians with guidance on strategies for improving disease awareness, increasing collaborative decision-making, and promoting self-management among patients with severe asthma.

Faculty

William W. Busse, MD
Professor of Medicine
Division of Allergy, Pulmonary, and Critical Care Medicine
School of Medicine and Public Health
University of Wisconsin
Madison, Wisconsin


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

William W. Busse, MD
Royalty: Elsevier
Consulting Fees: AstraZeneca Pharmaceuticals LP, Genentech, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Sanofi Genzyme and Regeneron Pharmaceuticals, Teva Pharmaceuticals
Data Monitoring Boards/Study Oversight Committees: Boston Scientific, Genentech, ICON Clinical Research Ltd.

The Integrity CE planners and managers have nothing to disclose.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of November 20, 2018 through November 20, 2019 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Sanofi Genzyme and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information for Questions About the Activity

For information about the ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or via email at information@integrityce.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Statement of Commercial Support

Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

0.50 CME
The France Foundation
Spinal Muscular Atrophy Expert Discussion Conference Series — Transformative Treatment for SMA

Spinal Muscular Atrophy Expert Discussion Conference Series — Transformative Treatment for SMA

Start

Conference Series: Part 2 of 3

Activity Details

Free CME
0.50 AMA PRA Category 1 Credit(s)
Released: August 21, 2018
Expires: August 20, 2019
30 minutes to complete

Accredited By

Target Audience

Neurologists, pediatric neurologists, neuromuscular specialists, pediatricians, genetic counselors, and other clinicians who see patients with spinal muscular atrophy

Learning Objectives

  • Explore the potential implications of gene therapy for SMA
  • Summarize key clinical trial data on available/emerging treatments for SMA

Activity Description

As new therapies emerge for spinal muscular atrophy (SMA) that include gene replacement and gene modifying therapies, clinicians need to consider the expectations for these treatments. Experts, Dr. Eugenio Mercuri, Dr. Richard Finkel, and Dr. Gyula Acsadi, recently discussed these emerging therapies and their implications on the clinical disease state at an international meeting. This activity is a recording of their roundtable discussion with informative slides broken into 3 parts. The first part discusses diagnosis, genetics, and the role of SMN in SMA. Part 2 explains the results of emerging clinical trial data. The final activity is a practical discussion about the implications of these new therapies for this lethal disease. Discussion topics include the durability of new and emerging treatments and changes to the standards of care for patients with SMA. This education is an engaging update on SMA from the leading experts in the field.

Statement of Educational Need

Many clinicians have questions regarding the genetics of spinal muscular atrophy. In addition, carrier screening is not routinely done, despite ACOG recommendations. Routine newborn testing is currently being considered in many states and internationally. Identification of the neuromotor deficits associated with SMA (and other conditions) is often inaccurate or delayed. As new therapies emerge that include gene replacement and gene modifying therapies, clinicians need to consider the expectations of these treatments. Gene replacement therapy is still a mystery to most clinicians. New therapies prompt a reevaluation of current standards of SMA care.

Agenda

  • Gene splicing modifiers
  • Gene replacement therapy MOA
  • Clinical trial results

Faculty

Eugenio Mercuri, MD, PhD (Chair)
Professor of Pediatric Neurology
Catholic University of the Sacred Heart
Rome, Italy

Dr. Eugenio Mercuri is a consultant for AveXis, Biogen, F. Hoffmann-La Roche, and IONIS. He is a principal investigator for Biogen/IONIS and F. Hoffmann-La Roche studies.


Richard S. Finkel, MD
Division Chief of Neurology
Pediatric Neurology
Nemours Children’s Hospital
Orlando, Florida, United States

Dr. Richard Finkel is a consultant for AveXis, Biogen, Catabasis, Ionis, Mitobridge, Novartis, and Roche. He receives clinical trial support from AveXis, Biogen, Catabasis, Cytokinetics, Ionis, Lilly, MDA, NIH, ReveraGen, and Summit. Dr. Finkel owns stock in Roche. His partner holds several patents and receives patent licensing royalties from National Jewish Center and Children’s Hospital of Philadelphia.


Gyula Acsadi, MD, PhD
Division Head of Neurology and Rehabilitation
Professor of Pediatric Neurology
Connecticut Children’s Medical Center
University of Connecticut Medical School
Hartford, Connecticut, United States

Dr. Gyula Acsadi serves as a consultant for AveXis, Biogen, and Serepta. He is on the speakers bureau for Biogen and conducts contract research for Biogen, Italfarmaco, and Serepta.


Disclosure Policy

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest

Activity Staff Disclosure

The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The France Foundation designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.

Instructions for Receiving Credit

  • There are no fees for participating in and receiving credit for this activity.
  • Review the activity objectives and CME information.
  • Complete the CME activity
  • Complete the online posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
  • Complete the CME evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  • Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME certificate will be available for download.

Statement of Commercial Support

This activity is supported by an educational grant from AveXis, Inc.

Disclaimer Statement

The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.

Disclosure of Unlabeled Use

TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.50 CME
The France Foundation
Spinal Muscular Atrophy Expert Discussion Conference Series — Questions About SMA Treatment

Spinal Muscular Atrophy Expert Discussion Conference Series — Questions About SMA Treatment

Start

Conference Series: Part 3 of 3

Activity Details

Free CME
0.50 AMA PRA Category 1 Credit(s)
Released: August 21, 2018
Expires: August 20, 2019
30 minutes to complete

Accredited By

Target Audience

Neurologists, pediatric neurologists, neuromuscular specialists, pediatricians, genetic counselors, and other clinicians who see patients with spinal muscular atrophy

Learning Objectives

  • Explain the genetic aspects of SMA, including its recessive nature, carriers, and recommendations for genetic screening
  • Explore the potential implications of gene therapy for SMA
  • Summarize key clinical trial data on available/ emerging treatments for SMA

Activity Description

As new therapies emerge for spinal muscular atrophy (SMA) that include gene replacement and gene modifying therapies, clinicians need to consider the expectations for these treatments. Experts, Dr. Eugenio Mercuri, Dr. Richard Finkel, and Dr. Gyula Acsadi, recently discussed these emerging therapies and their implications on the clinical disease state at an international meeting. This activity is a recording of their roundtable discussion with informative slides broken into 3 parts. The first part discusses diagnosis, genetics, and the role of SMN in SMA. Part 2 explains the results of emerging clinical trial data. The final activity is a practical discussion about the implications of these new therapies for this lethal disease. Discussion topics include the durability of new and emerging treatments and changes to the standards of care for patients with SMA. This education is an engaging update on SMA from the leading experts in the field.

Statement of Educational Need

Many clinicians have questions regarding the genetics of spinal muscular atrophy. In addition, carrier screening is not routinely done, despite ACOG recommendations. Routine newborn testing is currently being considered in many states and internationally. Identification of the neuromotor deficits associated with SMA (and other conditions) is often inaccurate or delayed. As new therapies emerge that include gene replacement and gene modifying therapies, clinicians need to consider the expectations of these treatments. Gene replacement therapy is still a mystery to most clinicians. New therapies prompt a reevaluation of current standards of SMA care.

Agenda

  • What do we know and what do we need to know about treatments?
  • Questions from the audience

Faculty

Eugenio Mercuri, MD, PhD (Chair)
Professor of Pediatric Neurology
Catholic University of the Sacred Heart
Rome, Italy

Dr. Eugenio Mercuri is a consultant for AveXis, Biogen, F. Hoffmann-La Roche, and IONIS. He is a principal investigator for Biogen/IONIS and F. Hoffmann-La Roche studies.


Richard S. Finkel, MD
Division Chief of Neurology
Pediatric Neurology
Nemours Children’s Hospital
Orlando, Florida, United States

Dr. Richard Finkel is a consultant for AveXis, Biogen, Catabasis, Ionis, Mitobridge, Novartis, and Roche. He receives clinical trial support from AveXis, Biogen, Catabasis, Cytokinetics, Ionis, Lilly, MDA, NIH, ReveraGen, and Summit. Dr. Finkel owns stock in Roche. His partner holds several patents and receives patent licensing royalties from National Jewish Center and Children’s Hospital of Philadelphia.


Gyula Acsadi, MD, PhD
Division Head of Neurology and Rehabilitation
Professor of Pediatric Neurology
Connecticut Children’s Medical Center
University of Connecticut Medical School
Hartford, Connecticut, United States

Dr. Gyula Acsadi serves as a consultant for AveXis, Biogen, and Serepta. He is on the speakers bureau for Biogen and conducts contract research for Biogen, Italfarmaco, and Serepta.


Disclosure Policy

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest

Activity Staff Disclosure

The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The France Foundation designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.

Instructions for Receiving Credit

  • There are no fees for participating in and receiving credit for this activity.
  • Review the activity objectives and CME information.
  • Complete the CME activity
  • Complete the online posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
  • Complete the CME evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  • Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME certificate will be available for download.

Statement of Commercial Support

This activity is supported by an educational grant from AveXis, Inc.

Disclaimer Statement

The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.

Disclosure of Unlabeled Use

TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.25 CME
The France Foundation
Spinal Muscular Atrophy Expert Discussion Conference Series — What Causes SMA? Genetics, Diagnosis, and the Role of SMN

Spinal Muscular Atrophy Expert Discussion Conference Series — What Causes SMA? Genetics, Diagnosis, and the Role of SMN

Start

Conference Series: Part 1 of 3

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: August 21, 2018
Expires: August 20, 2019
15 minutes to complete

Accredited By

Target Audience

Neurologists, pediatric neurologists, neuromuscular specialists, pediatricians, genetic counselors, and other clinicians who see patients with spinal muscular atrophy

Learning Objectives

  • Explain the genetic aspects of SMA, including its recessive nature, carriers, and recommendations for genetic screening
  • Describe criteria for SMA diagnosis

Activity Description

As new therapies emerge for spinal muscular atrophy (SMA) that include gene replacement and gene modifying therapies, clinicians need to consider the expectations for these treatments. Experts, Dr. Eugenio Mercuri, Dr. Richard Finkel, and Dr. Gyula Acsadi, recently discussed these emerging therapies and their implications on the clinical disease state at an international meeting. This activity is a recording of their roundtable discussion with informative slides broken into 3 parts. The first part discusses diagnosis, genetics, and the role of SMN in SMA. Part 2 explains the results of emerging clinical trial data. The final activity is a practical discussion about the implications of these new therapies for this lethal disease. Discussion topics include the durability of new and emerging treatments and changes to the standards of care for patients with SMA. This education is an engaging update on SMA from the leading experts in the field.

Statement of Educational Need

Many clinicians have questions regarding the genetics of spinal muscular atrophy. In addition, carrier screening is not routinely done, despite ACOG recommendations. Routine newborn testing is currently being considered in many states and internationally. Identification of the neuromotor deficits associated with SMA (and other conditions) is often inaccurate or delayed. As new therapies emerge that include gene replacement and gene modifying therapies, clinicians need to consider the expectations of these treatments. Gene replacement therapy is still a mystery to most clinicians. New therapies prompt a reevaluation of current standards of SMA care.

Agenda

  • Introduction to SMA
  • Role of SMN1 and SMN2 genes in SMA
  • Role of SMN protein in development

Faculty

Eugenio Mercuri, MD, PhD (Chair)
Professor of Pediatric Neurology
Catholic University of the Sacred Heart
Rome, Italy

Dr. Eugenio Mercuri is a consultant for AveXis, Biogen, F. Hoffmann-La Roche, and IONIS. He is a principal investigator for Biogen/IONIS and F. Hoffmann-La Roche studies.


Richard S. Finkel, MD
Division Chief of Neurology
Pediatric Neurology
Nemours Children’s Hospital
Orlando, Florida, United States

Dr. Richard Finkel is a consultant for AveXis, Biogen, Catabasis, Ionis, Mitobridge, Novartis, and Roche. He receives clinical trial support from AveXis, Biogen, Catabasis, Cytokinetics, Ionis, Lilly, MDA, NIH, ReveraGen, and Summit. Dr. Finkel owns stock in Roche. His partner holds several patents and receives patent licensing royalties from National Jewish Center and Children’s Hospital of Philadelphia.


Gyula Acsadi, MD, PhD
Division Head of Neurology and Rehabilitation
Professor of Pediatric Neurology
Connecticut Children’s Medical Center
University of Connecticut Medical School
Hartford, Connecticut, United States

Dr. Gyula Acsadi serves as a consultant for AveXis, Biogen, and Serepta. He is on the speakers bureau for Biogen and conducts contract research for Biogen, Italfarmaco, and Serepta.


Disclosure Policy

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest

Activity Staff Disclosure

The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The France Foundation designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.

Instructions for Receiving Credit

  • There are no fees for participating in and receiving credit for this activity.
  • Review the activity objectives and CME information.
  • Complete the CME activity
  • Complete the online posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
  • Complete the CME evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  • Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME certificate will be available for download.

Statement of Commercial Support

This activity is supported by an educational grant from AveXis, Inc.

Disclaimer Statement

The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.

Disclosure of Unlabeled Use

TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

1.00 CME
University of California, San Diego School of Medicine
Issues and Updates in Hereditary Angioedema

Issues and Updates in Hereditary Angioedema

Start

Jointly Provided By

University of California, San Diego School of Medicine and RMEI Medical Education, LLC.

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit
Released: December 27, 2017
Expires: December 27, 2018
1.0 hour to complete

Media

Internet

Target Audience

This activity has been designed to meet the educational needs of allergy/immunology physicians, allergy/immunology NPs and PAs, dermatology physicians, dermatology NPs and PAs.

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Recognize the possibility of hereditary angioedema (HAE) in patients who present with angioedema and integrate a diagnostic workup for angioedema that includes analysis for the various types of HAE (Type I, Type II, and normal C1-INH)
  2. Incorporate current, novel, and emerging treatments for HAE based on an understanding of their efficacy, safety, and guidance for use

Activity Description

This interactive multi-challenge activity addresses issues and updates in HAE. Based on the proceedings from a live continuing medical education series, it contains slides, expert audio, and commentary on some of the most current and important topics in HAE. Patient case challenges allow you to test your knowledge and skill in diagnosing and treating this important disease. Commentary from faculty experts will increase your understanding of the newest developments in HAE.

Statement of Educational Need

The treatment of hereditary angioedema (HAE) is rapidly evolving. After many years of limited treatment options, several effective medications for HAE have been introduced into clinical practice over the past 8 years. Now, a second wave of novel therapies are poised to reach the clinic. While the impact of these treatments is not yet known, it is likely the HAE treatment paradigm will shift yet again given the broadening therapeutic options available to physicians and patients.

Faculty

Marc A. Riedl, MD, MS
Professor of Medicine 
Clinical Director, US HAEA Angioedema Center 
Division of Rheumatology, Allergy and Immunology 
University of California, San Diego 
San Diego, CA


Michael E. Manning, MD, FAAAAI, FACAAI
President/Medical Director 
Medical Research of Arizona 
Allergy, Asthma & Immunology Associates, Ltd. 
Scottsdale, AZ


Daniel F. Soteres, MD, MPH
Physician Partner
Asthma & Allergy Associates and Research Center
Colorado Springs, CO


Disclosure of Conflicts of Interest

It is the policy of the University of California, San Diego School of Medicine to ensure balance, independence, objectivity, and scientific rigor. All persons involved in the selection, development, and presentation of content are required to disclose any real or apparent conflicts of interest. All conflicts of interest will be resolved prior to an educational activity being delivered to learners through one of the following mechanisms: 1) altering the financial relationship with the commercial interest, 2) altering the individual’s control over CME content about the products or services of the commercial interest, and/or 3) validating the activity content through independent peer review. All persons are also required to disclose any discussions of off label/unapproved uses of drugs or devices. Persons who refuse or fail to disclose will be disqualified from participating in the CME activity. Participants will be asked to evaluate whether the speaker’s outside interests reflect a possible bias in the planning or presentation of the activity. This information is used to plan future activities.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

  • Marc A. Riedl, MD, MS, has affiliations with CSL Behring, Pharming, Shire (Speakers Bureau); BioCryst, CSL Behring, Ionis, Pharming, Shire (Research); Adverum, Alnylam, BioCryst, CSL Behring, KalVista, Pharming, Shire (Consulting Fees)
  • Michael E. Manning, MD, FAAAAI, FACAAI, has affiliations with CSL Behring, Dyax, Pharming, Shire (Speakers Bureau); BioCryst, CSL Behring, Dyax, Pharming, Shire (Research); CSL Behring, Pharming, Shire (Advisory Board); CSL Behring (Consulting Fees)
  • Daniel F. Soteres, MD, MPH, has affiliations with CSL Behring, Pharming, Shire (Speakers Bureau); CSL Behring, Shire (Research); CSL Behring, Shire (Advisory Board); CSL Behring, Pharming, Shire (Consulting Fees)

The CME staff, meeting planners, and CME committee reviewers do not have any relevant financial relationships to disclose.

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views of the University of California, San Diego.

Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of California, San Diego School of Medicine and RMEI Medical Education, LLC. The University of California, San Diego School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The University of California, San Diego School of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Cultural Competency
This activity is in compliance with California Assembly Bill 1195 which requires CME courses with patient care components to include curriculum in the subjects of cultural and linguistic competencies. Cultural competency is defined as a set of integrated attitudes, knowledge, and skills that enables healthcare professionals or organizations to care effectively for patients from diverse cultures, groups, and communities. Linguistic competency is defined as the ability of a physician or surgeon to provide patients who do not speak English or who have limited ability to speak English, direct communication in the patient's primary language. Cultural and Linguistic Competency was incorporated into the planning of this activity. Additional resources on cultural and linguistic competency and information about AB1195 can be found on the UC San Diego CME website at http://cme.ucsd.edu.

How to Receive Credit

The estimated time to complete this activity is 1 hour. To obtain credit, participants should view the presentation, answer the multiple-choice post-test questions, and complete the evaluation form online to receive a certificate.

Physicians/DOs who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.

Statement of Commercial Support

The activity is supported in part by educational grants from CSL Behring, Pharming Healthcare, Inc., and Shire.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Hardware/Software Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.